F049 Pediatric Dermatology M&M
DESCRIPTION
Morbidity and mortality sessions provide caregivers with a structured forum to review adverse outcomes in medicine. Our session will be a case-based review of complications encountered while caring for children in both inpatient and outpatient settings. We will review cases that provide teaching points to improve care by decreasing errors in communication and practice. Cases will also solidify the difference between adverse events that can be avoided and those that are inherent risks of illness. This forum is a blameless environment to help all of us learn.
LEARNING OBJECTIVES
Identify gaps in communication that lead to error.
Differentiate adverse events that are risks of therapy or disease and those that result from error.
Discuss strategies for handling and coping with adverse events.
SCHEDULE
3:30 PM
Introduction
Adena Rosenblatt, MD, PhD, FAAD
3:45 PM
Case presentation and Q&A
Lisa Shen, MD, FAAD
4:10 PM
Case presentation and Q&A
Julie Marcia Dhossche, MD, FAAD
4:35 PM
Case presentation and Q&A
Karen Chernoff, MD, FAAD
5:05 PM
Case presentation and Q&A
Fernanda Bellodi Schmidt, MD
DIRECTOR
Adena Rosenblatt, MD, PhD, FAAD
SPEAKERS
Fernanda Bellodi Schmidt, MD
Karen Chernoff, MD, FAAD
Julie Marcia Dhossche, MD, FAAD
Lisa Shen, MD, FAAD
DISCLOSURES
Fernanda Bellodi Schmidt, MD
Abeona Therapeutics – Investigator(Grants/Research Funding); Eli Lilly – Investigator(Grants/Research Funding); Primus Pharmaceuticals – Advisory Board(Honoraria); Timber Pharmaceuticals – Investigator(Grants/Research Funding);
Karen Chernoff, MD, FAAD
No financial relationships exist with ineligible companies.
Julie Marcia Dhossche, MD, FAAD
No financial relationships exist with ineligible companies.
Adena Rosenblatt, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Lisa Shen, MD, FAAD
No financial relationships exist with ineligible companies.